Zolpidem

Selective action at the alpha-1 subunit of the GABA-A receptor characterizes zolpidem, a Schedule IV imidazopyridine sedative-hypnotic classified as a “Z-drug” along with zaleplon and eszopiclone. Laboratory testing applications include drugs of abuse screening, forensic toxicology investigations, postmortem toxicology, driving under the influence of drugs (DUID) cases involving sleep-driving and complex sleep behaviors, pain management compliance monitoring, and clinical toxicology assessments in emergency departments. UTAK’s Benzodiazepines Plus, Miscellaneous Panel, and SAMHSA CONFIRM panels contain zolpidem in lyophilized and frozen urine, whole blood, and oral fluid matrices at multiple concentration levels, supporting both immunoassay screening and confirmation methods. Stock and custom QC solutions can incorporate related sedative-hypnotics and benzodiazepines such as alprazolam, diazepam, lorazepam, temazepam, triazolam, midazolam, carisoprodol, and other commonly monitored analytes to address your laboratory’s comprehensive drugs of abuse and sedative-hypnotic testing requirements.